Browsing by Author "Zelenak, Christine (36873788500)"
Now showing 1 - 3 of 3
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Early NT-proBNP and MR-proANP associated with QoL 1 year after acutely decompensated heart failure: secondary analysis from the MOLITOR trial(2019) ;Zelenak, Christine (36873788500) ;Chavanon, Mira-Lynn (14048024000) ;Tahirovic, Elvis (24339336300) ;Trippel, Tobias Daniel (16834210300) ;Tscholl, Verena (54982696400) ;Stroux, Andrea (10139008600) ;Veskovic, Jovan (56951285600) ;Apostolovic, Svetlana (13610076800) ;Obradovic, Danilo (35731962400) ;Zdravkovic, Marija (24924016800) ;Loncar, Goran (55427750700) ;Störk, Stefan (6603842450) ;Herrmann-Lingen, Christoph (6603417225)Düngen, Hans-Dirk (16024171900)Aim: Heart failure negatively impacts quality of life (QoL), which in turn contributes to an adverse long-term prognosis. We aimed at identifying biomarker trajectories after an episode of acutely decompensated heart failure (ADHF) that differ between patients showing average versus impaired QoL 1 year later, thus allowing to predict impaired QoL. Methods: Biomarkers were repeatedly measured throughout the year in 104 ADHF patients. QoL was assessed at discharge and 1 year after ADHF. Logistic regression and receiver operating characteristic analyses were used to identify predictors of impaired QoL while controlling psychosocial confounders. Results: MR-proANP predicted impaired physical and mental QoL. NT-proBNP measurements were important predictors for poor physical QoL. Conclusion: MR-proANP and NT-proBNP predict poor QoL after an epidode of ADHF. The trial is registered at http://clinicaltrials.gov as MOLITOR (IMpact of therapy optimisation On the Level of biomarkers in paTients with Acute and Decompensated ChrOnic HeaRt Failure) with unique identifier: NCT01501981. © 2019 Future Medicine Ltd. - Some of the metrics are blocked by yourconsent settings
Publication Early NT-proBNP and MR-proANP associated with QoL 1 year after acutely decompensated heart failure: secondary analysis from the MOLITOR trial(2019) ;Zelenak, Christine (36873788500) ;Chavanon, Mira-Lynn (14048024000) ;Tahirovic, Elvis (24339336300) ;Trippel, Tobias Daniel (16834210300) ;Tscholl, Verena (54982696400) ;Stroux, Andrea (10139008600) ;Veskovic, Jovan (56951285600) ;Apostolovic, Svetlana (13610076800) ;Obradovic, Danilo (35731962400) ;Zdravkovic, Marija (24924016800) ;Loncar, Goran (55427750700) ;Störk, Stefan (6603842450) ;Herrmann-Lingen, Christoph (6603417225)Düngen, Hans-Dirk (16024171900)Aim: Heart failure negatively impacts quality of life (QoL), which in turn contributes to an adverse long-term prognosis. We aimed at identifying biomarker trajectories after an episode of acutely decompensated heart failure (ADHF) that differ between patients showing average versus impaired QoL 1 year later, thus allowing to predict impaired QoL. Methods: Biomarkers were repeatedly measured throughout the year in 104 ADHF patients. QoL was assessed at discharge and 1 year after ADHF. Logistic regression and receiver operating characteristic analyses were used to identify predictors of impaired QoL while controlling psychosocial confounders. Results: MR-proANP predicted impaired physical and mental QoL. NT-proBNP measurements were important predictors for poor physical QoL. Conclusion: MR-proANP and NT-proBNP predict poor QoL after an epidode of ADHF. The trial is registered at http://clinicaltrials.gov as MOLITOR (IMpact of therapy optimisation On the Level of biomarkers in paTients with Acute and Decompensated ChrOnic HeaRt Failure) with unique identifier: NCT01501981. © 2019 Future Medicine Ltd. - Some of the metrics are blocked by yourconsent settings
Publication Regional differences in health-related quality of life in elderly heart failure patients: results from the CIBIS-ELD trial(2017) ;Chavanon, Mira-Lynn (14048024000) ;Inkrot, Simone (35784615000) ;Zelenak, Christine (36873788500) ;Tahirovic, Elvis (24339336300) ;Stanojevic, Dragana (58530775100) ;Apostolovic, Svetlana (13610076800) ;Sljivic, Aleksandra (55848628200) ;Ristic, Arsen D. (7003835406) ;Matic, Dragan (25959220100) ;Loncar, Goran (55427750700) ;Veskovic, Jovan (56951285600) ;Zdravkovic, Marija (24924016800) ;Lainscak, Mitja (9739432000) ;Pieske, Burkert (35499467500) ;Herrmann-Lingen, Christoph (6603417225)Düngen, Hans-Dirk (16024171900)Aim: Patient-reported outcomes such as health-related quality of life (HRQoL) are main treatment goals for heart failure (HF) and therefore endpoints in multinational therapy trials. However, little is known about country-specific differences in HRQoL and in treatment-associated HRQoL improvement. The present work sought to examine those questions. Methods and results: We analysed data from the Cardiac Insufficiency Bisoprolol Study in Elderly (CIBIS-ELD) trial, in which patients from central and south-eastern Europe completed the HRQoL questionnaire SF-36 at baseline and the end of a 12-week beta-blocker up-titration (follow-up). 416 patients from Serbia (mean age 72.21 years, 69% NYHA-class I–II, 27.4% women) and 114 from Germany (mean age 73.64 years, 78.9% NYHA-class I–II, 47.4% women) were included. Controlling for clinical variables, the change in mental HRQoL from baseline to follow-up was modulated by Country: Serbian patients, Mbaseline = 37.85 vs. Mfollow−up = 40.99, t(526) = 5.34, p <.001, reported a stronger increase than Germans, Mbaseline = 37.66 vs. Mfollow−up = 38.23, t(526) = 0.68, ns. For physical HRQoL, we observed a main effect of Country, MSerbia = 39.28 vs. MGermany = 35.29, t(526) = 4.24, p <.001. Conclusion: We observed significant differences in HF patients from Germany and Serbia and country-specific differences between Serbian and German patients in mean physical HRQoL. Changes in mental HRQoL were modulated by country. Those results may reflect psychological, sociocultural, aetiological differences or regional differences in phenotype prevalence. More importantly, they suggest that future multinational trials should consider such aspects when designing a trial in order to avoid uncertainties aligned to data interpretation and to improve subsequent treatment optimisation. © 2017, Springer-Verlag Berlin Heidelberg.